Anti-PD-1 Monoclonal Antibody With Standard of Care Improves Outcomes for BCG-Naïve Bladder Cancer

Source: Pharmacy Times articles

A study reveals sasanlimab enhances event-free survival in high-risk bladder cancer patients, offering new hope against disease recurrence.
Read More